Pharmaceutics (Dec 2023)

Natural Chalcones and Derivatives in Colon Cancer: Pre-Clinical Challenges and the Promise of Chalcone-Based Nanoparticles

  • Soufyane Hba,
  • Suzan Ghaddar,
  • Hicham Wahnou,
  • Aline Pinon,
  • Riad El Kebbaj,
  • Christelle Pouget,
  • Vincent Sol,
  • Bertrand Liagre,
  • Mounia Oudghiri,
  • Youness Limami

DOI
https://doi.org/10.3390/pharmaceutics15122718
Journal volume & issue
Vol. 15, no. 12
p. 2718

Abstract

Read online

Colon cancer poses a complex and substantial global health challenge, necessitating innovative therapeutic approaches. Chalcones, a versatile class of compounds with diverse pharmacological properties, have emerged as promising candidates for addressing colon cancer. Their ability to modulate pivotal signaling pathways in the development and progression of colon cancer makes them invaluable as targeted therapeutics. Nevertheless, it is crucial to recognize that although chalcones exhibit promise, further pre-clinical studies are required to validate their efficacy and safety. The journey toward effective colon cancer treatment is multifaceted, involving considerations such as optimizing the sequencing of therapeutic agents, comprehending the resistance mechanisms, and exploring combination therapies incorporating chalcones. Furthermore, the integration of nanoparticle-based drug delivery systems presents a novel avenue for enhancing the effectiveness of chalcones in colon cancer treatment. This review delves into the mechanisms of action of natural chalcones and some derivatives. It highlights the challenges associated with their use in pre-clinical studies, while also underscoring the advantages of employing chalcone-based nanoparticles for the treatment of colon cancer.

Keywords